June 13, 2019 Making Downstream Processing Continuous and Robust
Current biomanufacturing is driven to pursue continuous processing for cost reduction and increased productivity, especially for monoclonal antibody (MAb) production and manufacturing. Although many technologies are now available and have been implemented in biodevelopment, implementation for large-scale production is still in its infancy.
BPI asked a number of industry representatives to comment on issues when implementing continuous downstream processing at large-scale. Please find the full virtual roundtable including the expert opinions of our DSP Development colleagues on the website of BPI.
Rentschler Biopharma SE
Dr. Cora Kaiser
Senior Director Corporate Communication